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ABSTRACT
Although inhibition of autophagy has been implicated in the onset and progression 
of cancer cells, it is still unclear whether its dysregulation at early stages of 
tumorigenesis plays an oncogenic or a tumor suppressor role. To address this question, 
we employed the Resistant-Hepatocyte rat model to study the very early stages of 
hepatocellular carcinoma (HCC) development. We detected a different autophagy-
related gene expression and changes in the ultrastructural profile comparing the most 
aggressive preneoplastic lesions, namely those positive for the putative progenitor 
cell marker cytokeratin-19 (KRT-19) with the negative ones. The ultrastructural and 
immunohistochemical analyses of KRT-19-positive preneoplastic hepatocytes showed 
the presence of autophagic vacuoles which was associated with p62, Ambra1 and 
Beclin1 protein accumulation suggesting that a differential modulation of autophagy 
occurs at early stages of the oncogenesis in KRT-19-positive vs negative lesions. 
We observed an overall decrease of the autophagy-related genes transcripts and a 
strong up-regulation of miR-224 in the KRT-19-positive nodules. Interestingly, the 
treatment with the autophagy inducer, Amiodarone, caused a marked increase in 
the proliferation of KRT-19 positive preneoplastic lesions associated with a strong 
increase of their size; by contrast, Chloroquine, an inhibitor of the autophagic process, 
led to their reduction. These results show that autophagy modulation is a very early 
event in hepatocarcinogenesis and is restricted to a hepatocytes subset in the most 
aggressive preneoplastic lesions. Our findings highlight the induction of autophagy 
as a permissive condition favouring cancer progression indicating in its inhibition a 
therapeutic goal to interfere with the development of HCC.
INTRODUCTION
The term autophagy identifies the basic self-
degradative physiological process by which the cell 
removes worn-out or damaged components, such as 
protein aggregates, mitochondria, Endoplasmic Reticulum 
(ER), peroxisomes and intracellular pathogens [1-3]. 
Autophagy is evolutionarily conserved and involves 
the double-membrane sequestration and lysosomal 
breakdown of the cargo [1-3]. Although there is a basal 
autophagy in the cell, this process is further induced in 
response to stress, e.g. nutrient deprivation, hypoxia and 
pressure overload to catabolize cellular substrates and 
generate energy [4]. Defects in the autophagy machinery 
have been associated with the pathogenesis of the major 
human diseases including cancer [1,4]. Three major 
forms of autophagy have been described: micro-, macro- 
and chaperone-mediated autophagy, all involving the 
lysosomal breakdown of sequestered material [4,5]. The 
emerging role of macro-autophagy (from here on referred 
to as autophagy) has been the focus of recent cutting edge 
research and it is now accepted that it plays a critical role 
in both health and disease [1-3]. Autophagy is a multistep 
process involving its induction, the development of an 
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isolation membrane, the completion and maturation of 
an ‘autophagosome’ containing cytosolic components 
for recycling and the ultimate fusion with a lysosome 
(forming the autophagolysosome) for degradation by 
lysosomal enzymes [1-3].
While oncogenic transformation and tumour 
development are associated with resistance to, or loss 
of, the apoptotic pathway, an increasingly number of 
experimental data suggest that autophagy imbalance 
plays an important role in tumorigenesis and is a relevant 
target for cancer therapy [1, 5-7]. Indeed, autophagy-
deficient mice develop a large number of spontaneous 
tumours, supporting the idea that autophagy acts as 
tumor suppression mechanism [6-7]. Moreover, the 
heterozygous deletion in mice of essential autophagy 
genes such as Beclin1 and Ambra1 leads to high incidence 
of spontaneous tumours [8, 9]. The role played by Beclin 
1 and Ambra1 as tumour suppressors is also evidenced 
by the identification of their binding partners, most of 
which are implicated in tumorigenesis, such as Bcl-2. The 
anti-apoptotic member of the bcl-2 family constitutively 
binds to Beclin1 and Ambra1 complex inhibiting 
autophagy induction [10]. Furthermore, overexpression 
of the positive regulator of Beclin1 UVRAG activates 
autophagy and suppresses tumour cell growth, whereas 
its down-regulation results in decreases autophagy levels 
and triggers uncontrolled cell proliferation [7, 8]. Finally, 
it has been recently published that Ambra1 regulates cell 
proliferation by facilitating the degradation of the proto-
oncogene c-Myc by favouring its dephosphorylation by 
PP2A and thereby reducing the cell division rate [8]. 
Although the current view is that autophagy acts as 
a tumour suppressor process it is now also emerging that 
some established cancers require autophagy to survive, 
thus suggesting a pro-tumour autophagy activity. In 
keeping with this notion, the Ras-dependent tumorigenesis 
has been shown to be associated to autophagy induction 
[11, 12]. It is also now clear that the genotype of an 
individual tumor influences the autophagic function. 
For instance, in melanoma, BRAF has a direct effect 
on autophagy regulation. In fact, the overexpression 
of the wild type BRAF vs the mutated BRAFV600E 
in melanoma cells leads to increased basal levels of 
autophagy [13].
The paradox of autophagy acting as both a cell 
survival pathway and a tumour suppressor pathway is 
now being in some way reconciled; the current view is that 
while autophagy suppresses tumour growth at early stages 
of oncogenesis, it promotes growth in established tumors 
[6, 11, 12]. However, due to several controversial data the 
exact role of autophagy in the different steps of cancer 
development, especially in hepatocellular carcinoma 
(HCC), remains elusive [14-16].
HCC is the third cause of cancer-related deaths 
worldwide, and is characterized by poor prognosis and 
few treatment options [17]. The development of HCC 
is a multistep process. HCCs arise most frequently in 
the setting of chronic liver inflammation and fibrosis 
due to viral infection, metabolic injury, toxic insults, 
or autoimmune reactions. These tumors originate from 
premalignant lesions, ranging from dysplastic foci to 
dysplastic hepatocyte nodules that are often seen in 
damaged and cirrhotic livers, and are more proliferative 
than the surrounding parenchyma [18]. Since no effective 
treatment for HCC exists and, upon diagnosis, most 
patients with advanced disease have a remaining lifespan 
of only 4–6 months, it is critical to detect cellular and 
molecular changes taking place in preneoplastic lesions 
and identify biomarkers and molecular targets useful for 
an early diagnosis and for therapy. 
Since the knowledge of molecular events occurring 
in early stages of HCC development is hampered by 
the difficulties in the histomorphologic distinction 
between non-malignant nodular lesions and early HCCs, 
animal models allowing the study of different stages of 
hepatocarcinogenesis, represent a very helpful tool to 
detect cellular and molecular alterations occurring in early 
preneoplastic stages. Therefore, in our present study, we 
employed the Resistant-Hepatocyte (R-H) model which 
allows dissecting the several steps of hepatocarcinogenesis 
and whose translational value has already been 
demonstrated [19-21], to investigate the role of autophagy 
in the early stages of HCC development. 
RESULTS 
Differential autophagy modulation takes place in 
early preneoplastic nodules
The R-H model allows dissecting the different 
steps of the carcinogenic process, as phenotypically 
distinct lesions can be identified at well-defined timings 
[19]. Therefore, it is possible to investigate changes in 
the autophagic machinery at very early times in HCC 
development. To this aim, we performed ultrastructural 
examination of preneoplastic nodules dissected from 
the surface of the liver exposed to the R-H model 
and developed 10 weeks after treatment with DENA. 
Electron microscopy of hepatocytes in the preneoplastic 
nodules revealed extensive morphological alterations 
of cytoplasmic organelles (Figure 1B) compared with 
control liver (Figure 1A). Most hepatocytes in the 
nodules displayed abnormal mitochondria (Figure 
1C), which appeared swollen with loss of cristae and 
ruptures of the outer membrane. No sign of clearance 
by autophagy of the degenerating mitochondria was 
visible. Autophagic vacuoles containing only partially 
degraded materials (Figure 1C) and lipid droplets 
accumulation were frequently observed (Figure 1D). 
All these features are indicative of an impairment of the 
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autophagic process, demonstrating that derangement of the 
autophagic machinery occurs at very early stages of HCC 
development.
Autophagy modulation in KRT-19+ negative vs 
positive preneoplastic nodules
We have previously shown in the R-H model 
[20,21] that although preneoplastic nodules positive for 
the putative progenitor cell marker cytokeratin-19 (KRT-
19+) represent a minority of the total preneoplastic lesions, 
most HCCs are positive for this marker. This suggests that 
KRT-19+ preneoplastic nodules have an advantage in the 
progression to malignancy, while KRT-19- lesions undergo 
spontaneous remodeling during the carcinogenic process, 
a previously described phenomenon [22]. Therefore, we 
wished to investigate as to whether autophagy modulation 
could be a general phenomenon of preneoplastic stages or 
it is restricted to the most aggressive (KRT-19+) lesions. 
Table 1: Percentage and number of KRT-19+/Ambra1+, KRT-19+/p62+ and KRT-19+/Beclin1+ nodules with respect to 
the total amount of KRT-19+ nodules.
Mean N° of 
GST-P+
nodules
Mean N° of 
KRT 19+
/GST-P+
nodules
Mean N° of 
Ambra1+
/KRT-19+
nodules
% of 
Ambra1+
/KRT-19+
nodules
Mean N° of 
p62+
/KRT-19+
nodules
% of p62+
/KRT-19+
nodules
Mean N° of 
Beclin1+
/KRT-19+
nodules
% of 
Beclin1+
/KRT-19+
nodules
74.6 ± 13.3 18.4 ± 4.0 18.2 ± 4.0 99.0 17.3 ± 4.0 94.0 13.0 ± 2.2 70.6
The analysis of serial liver sections was performed on a total number of 373 nodules, obtained from 5 rats.
Figure 1: Transmission electron microscopy of preneoplastic nodules. A. Representative image of control liver. Hepatocytes (H) 
typically display a large, round nucleus (N); numerous mitochondria (m) with regular matrix and prominent cristae. B. Ultrastructure of a 
preneoplastic hepatocyte (H). Irregular nucleus (N), extensive vacuolation (asterisks), lipid droplets accumulation (see arrows) characterize 
the preneoplastic modifications. C. Higher magnification of nodule hepatocytes revealed that mitochondria undergo pathological 
modifications, consisting of swelling and progressive loss of cristae. Autophagosomes containing only partially digested material are also 
visible (arrows). D. Lipid inclusions (LL) accumulation in the cytoplasm of preneoplastic hepatocytes. Original magnifications: A, B= 
x3000; C, D= x30000. 
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To this aim, immunohistochemistry analysis of typical 
autophagic markers, such as p62, Ambra1 and Beclin1, 
that are involved in the multistep process of autophagy, 
was performed on serial sections of livers from rats 
subjected to the R-H protocol and sacrificed 10 weeks 
after DENA. Interestingly, specific staining of KRT-19+ - 
but not of KRT-19- -preneoplastic lesions was observed by 
positivity of the liver sections for two other proteins, such 
as Ambra1 and Beclin1, involved in the early regulatory 
steps of the autophagic process and p62 which is mediating 
the recruitment of cargos in the autophagosomes (Figure 
2A, 2B). Remarkably, 99%, 94% and 71% of GST-P+/
KRT-19+ nodules were also positive for Ambra1, p62 
and Beclin1, respectively (Table 1). Almost none of 
KRT-19- nodules – nor the surrounding parenchymal 
tissue- exhibited staining for these proteins. As shown in 
Figure 2A and 2B, IHC revealed cytoplasmic and nuclear 
accumulation of p62 only in a subset of hepatocytes (about 
50% of the total) in the GST-P+/KRT-19+ nodules, but not 
in GST-P+/KRT-19- preneoplastic lesions, indicating that a 
marked differential modulation of the autophagic process 
occurs also inside the GST-P+/KRT-19+ nodules. 
Enhanced transcription is not the cause of the 
increased accumulation of p62, Ambra1 and 
Beclin1 
To assess whether the accumulation of p62, Ambra1 
and Beclin1 is the consequence of transcriptional or post-
transcriptional modifications of genes/gene products 
involved in the autophagic process, we performed 
qRT-PCR analysis of the expression of these and other 
autophagy-associated genes, on laser micro-dissected 
GST-P+/KRT-19+ preneoplastic nodules. As shown in 
Figure 3A and 3B, no increased transcription of any of 
the examined genes involved in the autophagic process 
was observed. Rather, we found down-regulation of some 
Figure 2: Autophagy impairment is restricted to a more aggressive subset of preneoplastic hepatic nodules. IHC on serial 
sections of liver from rats subjected to the R-H protocol and sacrificed 10 weeks after DENA. A. Presence of intense staining for Ambra1, 
Beclin1 and p62 in a nodule positive for GST-P and KRT-19 (magnification x4). A higher enlargement of the same nodule showing nuclear 
p62 staining (magnification x20). B. Absence of Ambra1, Beclin1 and p62 staining in a GST-P+/KRT-19- nodule (magnification x4).
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of them, such as Ulk1, Ambra1, p62, LC3 and FoxO3. 
These results clearly demonstrate that the accumulation 
of these proteins in aggressive preneoplastic lesions is not 
due to an active transcription. However, the interpretation 
of these findings should take into consideration that, as 
highlighted by the IHC, the accumulation of the Ambra1, 
p62 and Beclin1 has been detected only in about 50% of 
the hepatocytes. 
MiR-224 is highly expressed in KRT-19 positive 
nodules
Recently, it was reported that inhibition of 
autophagy in hepatitis B-associated human HCCs is 
responsible for the strong accumulation of miR-224 - 
one of the most up-regulated miRs in human cancer [23, 
24] - in these tumors [25]. Therefore, we investigated the 
expression of miR-224 in KRT-19+ preneoplastic lesions. 
As shown in Figure 3C, miR-224 was strongly up-
regulated in KRT-19 positive lesions (150-fold) compared 
to normal liver, supporting the notion that the increased 
miR-224 expression found in experimental and human 
HCC is most likely the consequence of its accumulation 
when autophagic machinery is deregulated. 
The autophagic inducer, Amiodarone, stimulates 
the growth of KRT-19+ nodules
The results so far obtained demonstrate that 
autophagy deregulation is an early event in HCC 
development and characterizes about 50% of the 
parenchymal cells in the most aggressive lesions. 
Since previous works suggested that autophagy mainly 
contributes to tumor suppression during the early stage of 
tumorigenesis, we wished to further investigate whether 
impairment of the autophagic process favours cancer 
progression. To address this question, we administered 
Amiodarone, an autophagy inducer [26], or chloroquine 
(CQ), an autophagy inhibitor [27], to nodule-bearing 
rats developed 6 weeks after DENA. Interestingly, while 
Amiodarone did not significantly modify the number of 
GST-P+ preneoplastic lesions (Figure 4A), an impressive 
Figure 3: Analysis of mRNA levels of autophagy-associated genes and miRNA-224. A. qRT-PCR analysis of Ulk1, Ambra1, 
Beclin1, Atg12, Atg5, p62 and FoxO3 mRNA in KRT-19+ nodules generated 10 weeks after treatment with DENA. Gene expression is 
reported as fold-change relative to age-matched controls; ***P<0.001, **P<0.01, NS: not significant. B. LC3 expression in KRT-19+ 
preneoplastic nodules. Gene expression is reported as fold-change relative to age-matched controls; *P<0.05. C. qRT-PCR analysis of 
miR-224 expression in KRT-19+ nodules. miR-224 expression is reported as fold-change relative to age-matched controls; ***P<0.0001.
Oncotarget5793www.impactjournals.com/oncotarget
increase of the size (Figure 4B, 4E) and of the % hepatic 
area (Figure 4C, 4E) occupied by these lesions was 
observed compared to the control group. These enhancing 
effects were associated with a strong increase in nodule 
hepatocyte proliferation (Figure 5A, 5B). Interestingly, 
Amiodarone also led to an increase of the percentage of 
KRT-19+ nodules (Figure 4D, 4E). On the opposite, when 
compared to untreated animals, the autophagic inhibitor 
CQ caused a decrease of the size and of the % hepatic 
area occupied by these lesions (Figure 4A-4C, 4E). 
Moreover, the % of KRT-19+ nodules was found to be 
significantly lower than that of the Amiodarone-treated 
group. Remarkably, treatment with CQ strongly inhibited 
proliferation of nodule hepatocytes (Figure 5C) when 
compared to either control- or Amiodarone-treated group.
Previous report [25] has shown that Amiodarone-
induced autophagy leads to a reduction of the tumor 
weight. Therefore, we wished to establish if the 
observed promoting effects on nodule growth induced by 
Amiodarone was associated with increased autophagy. 
To this aim, electron microscopy examination of nodules 
scooped out from the liver surface was performed. As 
shown in (Figure 6A), the fine structure of Amiodarone-
treated hepatocytes revealed a less damaged morphology; 
lipid droplets scattered in the cytoplasm and dilated 
intercellular space were observed; however, after 
Amiodarone treatment cells in the nodules displayed 
intact rough endoplasmic reticulum and mitochondria 
which were similar to that of normal untreated hepatocytes 
(Figure 6C). Electron microscopy was also performed 
Figure 4: Effect of Amiodarone and Chloroquine on the number of GST-P+ nodules, the mean GST-P+ area, the 
percentage of the area occupied by GST-P+ hepatocytes and the number of KRT-19+ nodules. Rats exposed to the R-H 
protocol were injected intraperitoneally with Amiodarone (30 mg/kg, four doses) or Chloroquine (CQ, 50 mg/kg, 4 doses) starting 2 weeks 
after 2-AAF withdrawal (6 weeks after treatment with DENA). Animals were euthanized 7 days after the treatment. Effect of Amiodarone 
and Chloroquine administration on the number of GSTP-positive nodules A., the mean GST-P-positive area B., the percentage of the area 
occupied by GST-P-positive hepatocytes C. and the number of KRT-19+ nodules D. Values are expressed as mean ± SEM. ***P<0.001, 
**P<0.01, *P<0.05, NS: not significant. E. GST-P and KRT-19 immunohistochemistry of liver sections from rats treated with Amiodarone 
and CQ (magnification x1.25).
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after CQ treatment; since the small size of CQ-treated rat 
nodules hampered the possibility of dissecting them from 
the liver, electron microscopy examination was performed 
in randomly selected areas of the liver. As shown in 
Figure 6B, EM analysis confirmed the inhibitory effect 
of CQ on autophagy; indeed, many vacuoles containing 
undigested cytoplasmic materials were observed. In 
addition, apoptotic and necrotic hepatocytes were often 
observed (data not shown). These findings indicate that 
while induction of autophagy stimulates the growth of 
preneoplastic lesions to HCC progression, inhibition of 
autophagy exerts the opposite effect. 
DISCUSSION 
Recent years have brought an enormous advance in 
the elucidation of the molecular machinery involved in 
mammalian autophagy [1-3]. Although the contribution 
of autophagy in tumour development is unquestioned, 
nonetheless, its role is not completely understood. 
Paradoxically, autophagy seems to play a dual role, acting 
as tumor promoter or tumor suppressor, depending on the 
tumor stage [28]. Numerous studies suggest that autophagy 
contributes to tumor suppression during the early stages 
of tumorigenesis [28-29]. This suppressive effect is 
likely due to some important functions of autophagy, 
such as defective organelle elimination in order to reduce 
oxidative stress and prevent DNA damage. During the late 
phases of tumorigenesis, autophagy is supposed to act as 
tumor promoter mechanism, enabling tumor cells to cope 
with high metabolic demand [6, 11].
As far as the role of autophagy in HCC development 
is concerned, it was reported that homozygous deficient 
mice for the autophagy genes ATG5 or ATG7 develop 
benign liver tumors that do not progress to metastatic 
cancer, which suggests that loss of autophagy may be 
sufficient for the initiation of tumorigenesis, but residual 
autophagy is required for the progression to cancer 
[6]. In line with these results, it was also reported that 
Figure 5: Effect of Amiodarone and Chloroquine administration on hepatocyte proliferation. A. GST-P, KRT-19 and BrdU 
IHC on serial sections of liver from rats subjected to the R-H protocol and sacrificed 7 weeks after DENA (magnification x4, inset x10). B. 
GST-P, KRT-19 and BrdU IHC on serial sections of liver from rats subjected to the R-H protocol, treated with four doses of Amiodarone 
and sacrificed 7 days after treatment (magnification x4, inset x10). C. GST-P, KRT-19 and BrdU IHC on serial sections of liver from rats 
subjected to the R-H protocol, treated with four doses of Chloroquine (CQ) and sacrificed 7 days after treatments (magnification x4, inset 
x10).
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autophagy suppressed hepatocarcinogenesis at early 
stages by protecting normal cell stability and promoted 
hepatocarcinogenesis at late stages by supporting tumor 
cells growth [28, 29]. Finally, Ambra1 haplodeficiency 
in mice leads to the development of liver tumors, and, in 
humans, Beclin1 expression was decreased in HCC tissues 
compared with adjacent non-tumoral tissues and Ambra1 
[4, 5].
In this study, we attempted to investigate the 
status of the autophagic process in the very early stages 
of hepatocarcinogenesis, taking advantage of the well-
established R-H model in the rat. The main findings 
stemming from our work indicate that modulation of 
autophagy i) is a very early event in the multistage process 
of hepatocarcinogenesis, and, ii) takes place selectively 
in in KRT-19+ preneoplastic lesions, but not in KRT-19- 
lesions. We have previously shown that although KRT-
19+ lesions represent a minority of the total preneoplastic 
lesions, most HCCs arising in this model are KRT-19+ [20, 
21]. Therefore, our results are in line with the observation 
that autophagy defects favour cancer development and 
loss of autophagy may increase the propensity of cells 
toward oncogenic transformation [30, 31]. 
Another relevant finding of the present work is 
the association between high miR-224 expression and 
autophagy impairment. A recent study demonstrated that 
inhibition of autophagy in HBV-associated human HCCs 
is the mechanism responsible for the strong accumulation 
of the mature form miR-224 in these tumors [25]. These 
results were also confirmed in liver tumors of HBV X 
gene transgenic mice. Importantly, miRNA-224, involved 
in cell proliferation, migration and invasion [32], is one 
of the most up-regulated miRs in rodent and human HCC 
[21-23, 24]. Indeed, our data show a drastic upregulation 
of miRNA-224 in those subset of nodules which are more 
aggressive and develop HCC.
An additional and novel finding of the present 
study is that while the autophagic inducer, Amiodarone, 
Figure 6: Ultrastructure of livers from nodule-bearing rats receiving amiodarone and chloroquine. A. TEM examination 
of liver tissues from rats receiving amiodarone show that endoplasmic reticulum (ER) appears well preserved and mitochondria (m) swelling 
and vacuolation are reduced compared to untreated preneoplastic liver D.; Few lipid inclusions (LL) are displayed by these hepatocytes 
compared to control liver C. B. Massive accumulation of autophagic vesicles is observed following treatment with chloroquine. Original 
magnifications: x3000.
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promotes a striking increase in the proliferation of nodular 
hepatocytes and the size of preneoplastic lesions, the 
inhibitor of autophagy, CQ, induces the opposite, thus 
leading to a decrease of the size of preneoplastic nodules. 
Similarly, Sun et al. [29] demonstrated that autophagy 
inhibition by CQ in the tumor-forming stage of DENA-
induced HCC, remarkably reduced tumor growth by 
decreasing cell survival and proliferation. Moreover, it has 
been also reported that the combination of sorafenib with 
chloroquine produced more pronounced tumor suppression 
in HCC, both in vivo and in vitro [33]. In further support 
of the hypothesis that inhibition of autophagy plays an 
anti-tumoral effect in the early stages of the carcinogenic 
process, Amiodarone increases the percentage of KRT-19+ 
nodules, endowed with a higher proliferative capacity. 
By contrast, inhibition of autophagy by CQ resulted in an 
almost complete loss of nodules positive for this marker. 
These results, in turn, suggest a link between autophagy 
and the accumulation of KRT-19. Indeed, we found that 
the most aggressive KRT-19-positive nodules express 
high level of Ambra1 that, through its interaction with 
the protein phosphatase PP2A, regulates the stability of 
the oncoprotein and pro-mitotic factor c-Myc [8]. Thus, 
the expression of Ambra1 can both potentiates autophagy 
through its interaction with Beclin1 and VPS34, as well as 
favours the proliferation of the most aggressive nodules 
by binding to PP2A.
In conclusion, the present work raised the 
interesting hypothesis that autophagy in the liver may act 
as an homeostatic mechanism limiting the progression 
of preneoplastic cells to a more malignant stage. The 
finding that the administration of chloroquine is able to 
rapidly reduce the size of the KRT-19+ preneoplastic 
lesions suggests that the pharmacological modulation of 
autophagy may represent a possible therapeutic approach 
to interfere with the development of HCC.
MATERIALS AND METHODS
Animals and treatment
Male Fischer rats were obtained from Charles 
River (Milano, Italy). Guidelines for Care and Use 
of Laboratory Animals were followed during the 
investigation. All animal procedures were approved by 
the Ethical Commission of the University of Cagliari and 
the Italian Ministry of Health. Animals were treated with 
a single dose of diethylnitrosamine (DENA, 150 mg/kg) 
and, two weeks later, were subjected to the R-H protocol, 
consisting of a 2 week-diet supplemented with 0.02% 
2-acetylaminofluorene (2-AAF) and a two/third partial 
hepatectomy (PH) [19]. Rats were then switched to basal 
diet all throughout the experiment and sacrificed 10 weeks 
after DENA administration (See Supp. Figure 1A.)
Another group of rats exposed to R-H protocol 
was given four doses of Chloroquine (50 mg/kg, Sigma-
Aldrich, C6628) or Amiodarone (30 mg/kg, Sigma-
Aldrich, A8423) starting 2 weeks after 2-AAF withdrawal 
(6 weeks after treatment with DENA). Rats were sacrificed 
7 days after the first dose (See Supp. Figure 1B and 1C). 
BrdU was given in drinking water (1mg/1ml) for 5 days 
before the sacrifice. 
Histology and immunohistochemistry
Liver sections were fixed in 10% formalin and 
included in paraffin or quickly frozen by immersion in 
liquid nitrogen and processed for hematoxylin-eosin, or 
GST-P and KRT-19 immunohistochemistry, as described 
[21]. We considered as KRT-19 positive, all those lesions 
exhibiting a KRT-19 positive area of at least 5% of the 
total area of the preneoplastic lesion. The average area 
occupied by KRT-19 positive hepatocytes was at least 
20% of the total area of the nodules microdissected for 
further analyses. Paraffin-embedded liver sections were 
used for p62, Ambra and Beclin 1 immunohistochemistry. 
Sections, were deparaffinized in xylene, incubated for 
5 min each in 100%, 90%, 70%, and 50% ethanol for 
rehydration and immersed in 10 mM sodium citrate, pH 
6.0, and microwaved for antigen retrieval. Endogenous 
peroxidase activity was blocked by 3% H
2
O
2
 for 5 min. 
After rinsing in phosphate-saline buffer (PBS) nonspecific 
antibody binding was reduced by incubating the sections 
with normal goat serum for 5 min. Sections were washed 
in PBS/1% BSA buffer and incubated with primary 
antibodies: rabbit anti-p62/SQSTM1 from MBL (Woburn, 
MA, USA) 1:400, rabbit anti AMBRA1 (ProSci) 1:100 
and rabbit anti-BECN1 Antibody (Santa Cruz) 1:50 were 
used. Reactions were visualized using a streptavidin-
biotin-immunoperoxidase system with DAB (Biogenex, 
San Ramon, CA) as chromogen substrates. Negative 
control staining was performed by omitting the primary 
antibody. Sections were counterstained in Mayer’s acid 
hemalum. 
RNA extraction and qRT-PCR
Total RNA was extracted from preneoplastic lesions 
with the MirVana kit (Life Technologies) and stored at 
-80ºC until needed. While RNA quantity was measured 
by NanoDrop ND1000 (Thermo Scientific), RNA integrity 
was assessed by Agilent Bioanalyzer 2100. Only RNA 
samples with a RIN (RNA Integrity Number) ≥ 7 were 
included in the study. RNA was retrotranscribed with 
High Capacity cDNA Reverse Transcription Kit (Life 
Technologies) using random primers. The expression 
levels of the examined genes were evaluated by Real-Time 
PCR analysis with an ABI PRISM 7300HT thermocycler 
(Life Technologies) on 6 samples of GST-P-positive 
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preneoplastic nodules. All samples were run in triplicate. 
For qRT-PCR, The Power SYBR Green PCR Master Mix 
(Life Technologies) was used. The complete list of primer 
sequences used is listed in Supp. Table 1. After checking 
the specificity of the PCR products with the melting curve, 
data were then normalized to GAPDH expression and the 
expression level of different targets was calculated by 
2-∆∆Ct. Analysis of LC3 expression was performed using 
specific TaqMan probes (Life Technologies) and GAPDH 
as endogenous control.
Analysis of MicroRNA-224
cDNA was synthesized using the TaqMan 
MicroRNA Reverse Transcription Kit (Life Technologies) 
in accordance with the manufacturer’s instructions. 
qRT-PCR amplification was performed with the reverse 
transcription product, TaqMan 2X Universal PCR Master 
Mix, No AmpErase UNG, miRNA-224 primers and probe 
mix (Life Technologies). The endogenous control 4.5S 
RNA(H) was used to normalize miRNA expression levels.
Laser capture microdissection
GST-P+/KRT-19+ nodules were identified by 
immunohistochemical staining of 6µm-thick frozen liver 
sections. Nodules microdissection was done on 16µm 
serial sections with a Leica LMD6000, as previously 
described [21]. 
Electron microscopy
Tissue samples were fixed with 2.5% glutaraldehyde 
(Assing Spa, R1012) in 0.1 M cacodylate buffer for 1 h 
at 4°C (sodium cacodylate trihydrate, Sigma-Aldrich, 
C4945), and postfixed in 1% osmium tetroxide (Sigma-
Aldrich, 75632) in 0.1 M cacodylate buffer for 1 h. 
Samples were then dehydrated in graded ethanol and 
embedded in Epon resin (AGAR 100, Agar Scientific 
R1045). Ultrathin sections were stained with 2% uranyl 
acetate (Sigma-Aldrich, 73943) and observed under a 
Zeiss EM900 transmission electron microscope. Images 
were captured digitally with a Mega View II digital 
camera (SIS; Zeiss).
Statistics
Data are expressed as mean ± standard deviation 
(SD) or mean ± standard error (SEM). Analysis of 
significance was done by t Student’s test using the 
GraphPad software (La Jolla, California).
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